Although the federal government has introduced a voluntary programme to lower prices for GLP-1 weight-loss medications, many U.S. states are reluctant to participate, leaving coverage gaps for Medicaid patients seeking obesity treatment.
For Medicaid patients waiting on coverage for GLP-1 weight-loss drugs, the problem is no longer whether Washington has created a path. It is whether states will actually use it. The Centres for Medicare and Medicaid Services has launched the BALANCE Model, a voluntary programme designed to negotiate lower prices for selected GLP-1 medicines on behalf of state Medicaid agencies and Medicare Part D plans, but the agency’s own model page still does not list any participating states.
BALANCE, short for Better Approaches to Lifestyle and Nutrition for Comprehensive Health, was opened to state Medicaid agencies in May 2026 and remains available until 1 January 2027. CMS says the aim is to pair discounted pricing with standardised coverage terms and lifestyle support, while manufacturers, states and plans all remain free to opt in. In an announcement about the model, Abe Sutton, director of the CMS Innovation Centre, said: “CMS will make GLP-1s more accessible for people with Medicare and Medicaid.”
That federal pitch comes against a far messier state-by-state reality. According to KFF, 13 state Medicaid programmes covered GLP-1s for obesity treatment under fee-for-service as of January 2026, down from 16 the previous autumn after California, New Hampshire, Pennsylvania and South Carolina ended coverage at the start of the year. North Carolina later restored its benefit. KFF has also said that states must cover GLP-1s when they are prescribed for approved medical uses such as type 2 diabetes, and, in some cases, for cardiovascular disease or moderate to severe obstructive sleep apnoea, but obesity-only coverage remains optional.
That distinction matters because the money involved is significant. KFF’s analysis of federal utilisation data found 8.4 million Medicaid prescriptions for GLP-1s in 2024, with gross spending of $8.6 billion. Those figures include drugs used for diabetes and other covered indications, so they do not measure obesity treatment alone, but they show why state officials are under pressure. A cheaper optional benefit is still a new expense, and for states that have already cut coverage to ease budget strain, a discount may not be enough to bring it back.
For patients, the result is a patchwork in which geography can matter as much as clinical need. Someone with obesity alone may have no coverage at all, while a patient with diabetes, established cardiovascular disease, sleep apnoea or noncirrhotic MASH may qualify under existing rules. Advocates have pointed out that obesity is common among Medicaid enrollees, yet the benefit remains limited in most states. The practical advice is simple: enrollees should check directly with their state Medicaid programme, pharmacy benefits line or prescriber before assuming anything has changed, and should not stop a prescribed medicine without medical guidance.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
